Q4 2020 13F Holders as of 12/31/2020
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
54M
-
Number of holders
-
65
-
Total 13F shares, excl. options
-
22.2M
-
Shares change
-
+1.5M
-
Total reported value, excl. options
-
$260M
-
Value change
-
+$20.2M
-
Number of buys
-
36
-
Number of sells
-
-14
-
Price
-
$11.71
Significant Holders of Fulcrum Therapeutics, Inc. - Common Stock, par value $0.001 per share (FULC) as of Q4 2020
67 filings reported holding FULC - Fulcrum Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q4 2020.
Fulcrum Therapeutics, Inc. - Common Stock, par value $0.001 per share (FULC) has 65 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 22.2M shares
of 54M outstanding shares and own 41.02% of the company stock.
Largest 10 shareholders include TRV GP III, LLC (5.96M shares), TRV GP IV, LLC (2.34M shares), RTW INVESTMENTS, LP (2.07M shares), FMR LLC (1.75M shares), Point72 Asset Management, L.P. (1.34M shares), Casdin Capital, LLC (1.24M shares), BlackRock Inc. (1.04M shares), Acuta Capital Partners, LLC (683K shares), Alphabet Inc. (678K shares), and VANGUARD GROUP INC (661K shares).
This table shows the top 65 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.